NanoViricides Signs Master Services Agreement with Only Orphans Cote for Orphan Drug Strategy
NanoViricides Inc. has signed a Master Services Agreement with Only Orphans Cote, LLC to develop an orphan drug strategy for its antiviral candidate NV-387. The agreement involves preparing and prosecuting orphan drug designation applications with the US FDA. This collaboration aims to advance NV-387's regulatory pathway as an orphan drug.
NanoViricides Inc. announced that it has signed a Master Services Agreement with Only Orphans Cote, LLC, a regulatory consulting firm. Under this agreement, Only Orphans Cote will assist NanoViricides in developing its orphan drug strategy for the antiviral drug candidate NV-387, as well as preparing and prosecuting relevant orphan drug designation applications with the US FDA Office of Orphan Products. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113041) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
